Dexamethasone in HELLP syndrome: experience in Bolivia

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Pharmacology

Background:

• HELLP syndrome is a severe obstetric complication characterized by hemolysis, elevated liver enzymes, and low platelet count.
• Management of HELLP syndrome often involves supportive care and timely delivery, but adjunctive therapies are being explored.

Purpose of the Study:

• To evaluate the effectiveness of postpartum dexamethasone in improving platelet counts in patients diagnosed with HELLP syndrome.
• To assess the utility of dexamethasone when administered according to physician discretion in real-world HELLP syndrome management.

Main Methods:

• A cross-sectional study involving 97 patients with HELLP syndrome.
• Comparison of outcomes between patients receiving postpartum dexamethasone (8 mg every 8 hours for 72 hours) and those who did not.
• Analysis of platelet count changes and HELLP syndrome classification (complete vs. partial).

Main Results:

• 43.3% of patients received dexamethasone.
• While groups were comparable, the dexamethasone group showed a significantly greater average platelet increase (88,408 vs. 27,448; p=0.001).
• Platelet counts normalized by the third day in both groups, despite initial differences.

Conclusions:

• Postpartum dexamethasone administration is associated with a significant increase in platelet count in HELLP syndrome.
• The studied regimen (8 mg every 8 hours for 72 hours) appears beneficial for managing thrombocytopenia in HELLP syndrome.
• Dexamethasone demonstrates utility as an adjunctive therapy in the postpartum management of HELLP syndrome.